PEG-MGF dosage and evidence

What is PEG-MGF?

How does PEG-MGF work?

It switches on satellite cells, the muscle's repair cells, and helps muscle mend after damage. The PEG coating makes it last longer than natural MGF, which is gone quickly.

What have studies in people found about PEG-MGF?

No person has been given PEG-MGF in any published study, and FDA says so plainly. The human study usually quoted on product pages measured the body's own MGF signal in muscle after exercise. Nobody in it was given any peptide.

• The human study that gets quoted is about the body's own MGF, not the injected peptide. 8 young men aged 25 to 36 and 7 older men aged 70 to 82 did 10 sets of 6 one-leg knee extensions at 80 percent of the most they could lift once. A sample of thigh muscle was taken 2.5 hours later. The gene message for MGF rose clearly in the young men and did not rise in the older men. A related IGF-1 gene message did not change in either group. At rest, MGF levels were about 100 times lower than the related form. No peptide was given to anyone.
• FDA's safety page on compounding substances, updated 22 April 2026: FDA has found no data on any person being given a product with PEG-MGF, by any route. It says it lacks key safety information, including whether it would harm people.
• No registered trials. A search for PEG-MGF on ClinicalTrials.gov finds one study, and it is of a long-acting growth hormone in short children, a different drug.
• A 2026 review of growth hormone peptides puts PEG-MGF in its lowest evidence group, with CJC-1295 without DAC and IGF-1 LR3. That group means no human studies checked by outside scientists exist at all, only guesses from lab and animal work and user stories online.
• The same review notes that adding the PEG chain changes how long a peptide lasts and where it goes in the body. So effects seen with the natural form, or with the short peptide alone, cannot be assumed for the PEG version that is sold.

What this does not tell you: Nothing is known about dose, absorption, how long it lasts, immune reactions or harm from PEG-MGF in a person, because nobody has measured any of it. The exercise study shows that one form of a gene message switches on in young muscle after heavy lifting, and less so with age. It does not show that injecting a lab-made PEG peptide does the same. It cannot, because the two are different things.

What do people who took PEG-MGF report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• The most repeated observation among people who have actually run it is that the coated PEG version works worse than the plain one. That is odd, because lasting longer in the body is the whole reason for the coating. It is the opposite of what the theory predicts.
• No noticeable short-term effect is the single most common report, and people who say that usually add that they cannot speak to whether anything happened over a longer run.
• Site injection for localised growth is the expectation newcomers arrive with, and it is corrected repeatedly by more experienced posters who say it acts through the whole body and that injecting into a muscle will not add size there.
• When people do describe something, it is recovery and fullness rather than visible growth, and it is nearly always alongside IGF-1 variants, growth hormone or a steroid cycle, so almost no account isolates it.
• Side effect discussion is unusually thin, with people describing nothing outwardly perceptible. Given how many of the same posters report feeling nothing at all, that absence is not informative.
• Bunk product is the explanation people reach for most often when it does nothing, particularly for material bought years ago from overseas suppliers, and that explanation is offered so readily that it makes the no-effect reports hard to interpret in either direction.

Sources: Peptide threads on MESO-Rx at thinksteroids.com, Steroidology and EliteFitness, plus the MESO-Rx compound profile discussion, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2003
  Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise

  This study is not about the injectable product at all. It looked at what the body makes on its own. After a hard weights session, young volunteers switched on more of the muscle growth signal inside their muscle. Older volunteers did not. Nobody was given PEG-MGF, or any drug. So it supports the idea that the signal matters for muscle growth and that it fades with age. It says nothing about whether injecting a modified version does anything in a person.

  Heavy resistance exercise raised MGF mRNA in muscle of young but not elderly volunteers; a study of endogenous expression, not of injected PEG-MGF.

  PMID 12562960 Journal of Physiology
• Review of studies2026
  The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

  A review of peptides that act on growth hormone and IGF-1, including PEG-MGF. It found no studies in people with a comparison group for the PEG-MGF product. It is banned in sport.

  Review covering PEG-MGF among GH/IGF-1 axis peptides: no controlled human trials of the pegylated product, and WADA prohibition applies.

  PMID 42395176 Frontiers in Endocrinology
• Review of studies2026
  Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

  Nobody has been given PEG-MGF in any study a regulator could find. FDA states it has identified no human exposure data for products containing PEG-MGF, by any route. It also says it lacks the information it would need to judge whether the compound would harm a person. This is a record of what does not exist. It is not a safety clearance and it is not a warning.

  FDA states it has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration, and lacks important information about whether it would cause harm if administered to humans. Updated 22 April 2026.

  Source U.S. Food and Drug Administration
• Review of studies2010
  Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration

  There is a real argument about whether the peptide being sold matches anything the human body makes. This review reports that the gene message for MGF is real. But the matching peptide has never been found: not in cells grown in a lab, not in the fluid around them, not in animal tissue, and not in any body fluid. One side says it is a genuine signal. The other says nobody has ever found it. The argument is not settled.

  States that no analogous peptide product of the Igf1 gene has been identified in or isolated from cultured cells, their conditioned medium, or in vivo animal tissues or biological fluids, which is the core of the dispute over whether synthetic MGF corresponds to anything the body makes.

  PMID 20130113 Endocrinology
• Animal study2003
  Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage

  In rats, after muscle damage, MGF switched on fast and briefly. That came before the muscle's repair cells woke up, and before the slower rise in the main form of IGF-1.

  After muscle damage in rats, the MGF splice variant was expressed rapidly and transiently, preceding satellite cell activation markers and the slower rise in systemic IGF-IEa.

  PMID 12692175 Journal of Physiology